Patents
Methods for introducing heterologous cells into fish to determine if the heterologous cells contain cancer cells or a pathogen
Patent Number: 7,408,095In general it is quickly forgotten that the biggest contribution of embryonic stem cell technology to medicine has not been in the area of actually generating therapeutics, but in development of model systems for studying diseases. It was only through the generation of knockout and transgenic animals that we as biologists were able to start deciphering the in vivo relevance of the genome.That...
Inventors: Serbedzija; George N. (Woburn, MA), McGrath; Patricia (Cambridge, MA)
Assignee: Phylonix Pharmaceuticals, Inc. (Cambridge, MA)
Date of First Priority Issue: Sunday February 22nd, 1998
Cosmetic compositions
Patent Number: 7,405,195The current patent covers a cosmetic generated using a variant of stromal derived factor (SDF-1) which the inventors termed stem cell active factor (SCAF). The natural function of SDF-1 is to call in stem cells to injured tissue, for example, after a heart attack there is a surge of SDF-1 which is involved in mediating mobilization of stem cells from the bone...
Inventors: Chen; Jidai (Bedford, MA), Cong; Yanping (Bedford, MA)
Assignee: Natural Beauty Bio-Technology Limited (Taipei, TW)
Date of First Priority Issue: Monday March 27th, 2006
1 Comment
1 Comment
Generation and use of dendritic cells
Patent Number: 7,405,076Plasticity of stem cells to differentiate into various tissues is often a subject of much debate, especially in terms of bone marrow hematopoietic stem cells becoming hepatocytes or cardiac cells. While some scientists state that a hematopoietic stem cell will only differentiate into blood cells, others point to the clinical evidence that administration of, for example bone marrow cells...
Inventors: Goldman; Michel (Brussels, BE), Bartholome; Emmanuel (Wemmel, BE), Buelens; Christel (Brussels, BE), Willems; Fabienne (Linkebeek, BE)
Assignee: Universite Libre de Bruxelles (Bruxelles, BE)
Date of First Priority Issue: Tuesday November 14th, 2000
Treatment of disease by inducing cell apoptosis
Patent Number: 7,402,567Hepatic fibrosis is associated with overproduction of collagen by stellate cells, as well as killing of hepatocytes by these cells. In some situations stem cells have demonstrated positive effects in clinical liver failure, both bone marrow stem cells, as well as mobilized peripheral blood stem cells.One mechanism by which stem...
Inventors: Chojkier; Mario (San Diego, CA), Buck; Martina (San Diego, CA)
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Friday October 27th, 2000
Longevity and PAPP-A
Patent Number: 7,402,724Pregnancy associated plasma protein-A (PAPP-A) is a protease that cleaves insulin-like growth factor binding-protein (IGFBP-4). PAPP-A is used experimentally as a diagnostic for myocardial infarction and also is indicative of various congenital abnormalities in utero. Interestingly, if PAPP-A is knocked out or functionally inactivated in mice, there is reduced levels of IGF activity AND the mice...
Inventors: Conover; Cheryl A. (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research (Rochester, MN)
Date of First Priority Issue: Friday January 4th, 2002
Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
Patent Number: 7,399,751This is a patent with priority in 1999 describing the use of genetically modified Sertoli cells for immune protection of implanted cells AND the use of the Sertoli cells themselves as the vector...genetic engineer with any gene is covered.This patent is part of the Canadian company Sernova's (CDNX:SVA.V) potent intellectual property portfolio...
Inventors: Kirkpatrick; Shaun A. (Tucson, AZ), Gores; Paul (Charlotte, NC), Halberstadt; Craig (Charlotte, NC)
Assignee: Sertoli Technologies, Inc. (Tucson, AZ)
Date of First Priority Issue: Thursday November 4th, 1999
Poly-Glu,Tyr for neuroprotective therapy
Patent Number: 7,399,740T regulatory cells are generally seen as antiinflammatory cells that are capable of suppressing pathological immune responses. These cells have been demonstrated to inhibit inflammatory pathologies such as bone resorption and transplant rejection. The current patent takes an opposite view of...
Inventors: Eisenbach-Schwartz; Michal (Rehovot, IL), Yoles; Ester (D.N. Nahal Sorek, IL), Hauben; Ehud (Hadera, IL)
Assignee: Yeda Research and Development Co. Ltd. (Rehovot, IL)
Date of First Priority Issue: Thursday June 28th, 2001
Mesenchymal precursor cell
Patent Number: 7,399,632Mesenchymal stem cell therapy is rapidly becoming a clinical reality. The beauty of this cell population is that it can be used in an "off the shelf" manner and does not appear to have many safety issues. Mesenchymal stem cells from the bone marrow have been patented by Osiris, whereas cells similar to mesenchymal stem cells have been found...
Inventors: Simmons; Paul (East Melbourne, AU), Zannettino; Andrew (Adelaide, AU), Gronthos; Stan (Bethesda, MD)
Assignee: Angioblast Systems, Incorporated (New York, NY)
Date of First Priority Issue: Tuesday July 15th, 2008
2 Comments
2 Comments
Stem cell-specific promoters and their use
Patent Number: 7,396,680The current patent covers the nucleic acid sequences for promoters. In the claims it just states "promoters" but the specification teaches that the promoters are specific to "stem cells". The examples part of the patent teaches that they are active in CD34 and CD133 cells found from cord blood.Being able to have patents on actual promoter sequences that are active...
Inventors: Shmelkov; Sergey V. (New York, NY), Rafii; Shahin (Great Neck, NY), Lin; Jun (Forest Hills, NY)
Assignee: Cornell Research Foundation, Inc. (Ithaca, NY)
Date of First Priority Issue: Friday October 31st, 2003
Cell delivery patch for myocardial tissue engineering
Patent Number: 7,396,537Various types of stem cell therapeutics are being attempted for cardiac conditions. On the one hand, it is known that infarcts induce mobilization of stem cells, and that this may be part of an endogenous regenerative response. Accordingly, the intravenous administration of mesenchymal stem cells has demonstrated a regenerative activity...
Inventors: Krupnick; Alexander (Philadelphia, PA), Kreisel; Daniel (Philadelphia, PA), Rosengard; Bruce R. (Gladwyne, PA)
Assignee: The Trustees of the University of Pennsylvania (Philadelphia, PA)
Date of First Priority Issue: Thursday February 28th, 2002